BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging ...

Otsuka Pharmaceutical is broadening its scope in rare disease, striking a deal to acquire Jnana Therapeutics and its lead drug candidate, a small molecule on track for pivotal testing in a ...

BOSTON, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Jnana Therapeutics, a clinical-stage biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging ...

Jnana Therapeutics is hitting early-stage momentum, adding additional validation in the form of new cash and a fresh Big Pharma collaboration just as its lead metabolic disease asset launches into ...

Jnana Therapeutics announced Tuesday that it raised $107 million in series C financing, more than doubling the $100 million it raised in its previous two rounds. Jnana also struck its second drug ...

Otsuka Pharmaceutical has picked up Boston-based Jnana Therapeutics for $800 million so the Japanese biotech can get its hands on a clinical-stage oral phenylketonuria (PKU) drug. Under the terms ...

Swiss pharma group Roche has doubled down on a partnership with Jnana Therapeutics, paying $50 million upfront to tap into the Boston-based biotech drug discovery platform for a wide-ranging push ...

Japan's Otsuka Pharma has agreed to take control of US biotech Jnana Therapeutics in a deal that will give it rights to a clinical-stage candidate for the rare metabolic disorder phenylketonuria ...

Like Walgude, hundreds of women in and around Velhe are aware of how low Hb affects their body, thanks to a seven-year-long blood testing campaign conducted by Jnana Prabodhini, an institution ...